Möchten Sie immer auf dem neuesten Stand bleiben?

The Annual General Meeting of Hofseth BioCare ASA will be held at the company's premises at Kipervikgata 13, 6003 Ålesund, on 28 April 2023 at 13:00 CET. The notice of the Annual General Meeting...

The Board of Directors of Hofseth BioCare ASA (“HBC”) has approved the financial statements for 2022 and the Company has today published the Annual Report and Sustainability Report for 2022. Please...

Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27 February 2023 purchased 200,000 shares in HBC at...

Christoph Baldegger, primary insider and member of the board of directors in Hofseth BioCare ASA ("HBC") has today purchased 100,000 shares in HBC at an average price of NOK 2.72 per share. As a...

Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 ...

Hofseth International AS ("HI"), a close associate of Hofseth Biocare ASA's (the "Company") board member Roger Hofseth, has notified the Company that HI has made the following purchases of shares in...

In Q4, the ingredients business continued to show favorable momentum with growth of 87 %, compared to same quarter last year on an underlying basis, generating sales revenues of NOK 34m, compared to...

Ødegård Prosjekt AS, a wholly owned company of Jon Olav Ødegård has today, 30 December 2022, bought 70,000 shares at an average price of NOK 2.91 per share. Jon Olav Ødegård is CEO and primary insider...

Highlights in the third quarter - HBC grew revenue by 105 % year-on-year shows strength of our business in uncertain times and during the third quarter, HBC signed contracts with new salmon...

The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and Stanford University School of Medicine. It aimed...